NASDAQ · Medical - Devices
COCH (COCH) Stock
$0.67
+1.71%
NASDAQ: COCH
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical Trial
TMX Newsfile · Jul 21, 2026
EXCLUSIVE: Envoy Medical Hits Key Clinical Trial Milestone for Fully Implanted Ear Implant
Benzinga · Jul 21, 2026
Envoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implant
TMX Newsfile · Jul 14, 2026
EXCLUSIVE: Envoy Medical Builds Momentum With Improved Cochlear Implant Trial Results
Benzinga · Jul 14, 2026
AngioDynamics (ANGO) Reports Q4 Loss, Beats Revenue Estimates
Zacks · Jul 14, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held40.50%
Institutions Held22.90%
Institutions Float Held38.50%
Peer Comparison
About COCH
COCH is led by CEO Brent T. Lucas, employs 42 people, headquartered in US, publicly traded since 2021.
COCH stock trades at $0.67 with a market capitalization of $14.02M. The stock is valued at a price-to-earnings (P/E) ratio of -0.74, price-to-book of 4.91, price-to-sales of 66.84. Over the past 52 weeks the stock has ranged between $0.36 and $1.89, and currently trades 64.6% below its 52-week high.
On profitability, COCH generates a return on equity (ROE) of 239.44% — well above the market average, a sign of a high-quality business, return on capital employed of -131.29%, an operating margin of 0.00%, a net profit margin of -98.76%.